ASCO 2024 – Summit peaks on ivonescimab surprise
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.